Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26129643 | 0.92 | SLC6A2 (0.40) | DRD2SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL255185 | 0.81 | KDM4E (0.44) | DRD2KDM4EL3MBTL1PIK3CD | |
| Hydrochloric Acid SCHEMBL190200 | 0.80 | KDM4E (0.43) | DRD2KDM4EL3MBTL1PIK3CD | |
| SCHEMBL4513010 | 0.79 | KDM4E (0.47) | KDM4EL3MBTL1PIK3CD | |
| Hydrochloric Acid SCHEMBL9148103 | 0.79 | KDM4E (0.42) | DRD2KDM4EL3MBTL1PIK3CD | |
| SCHEMBL7384750 | 0.79 | KDM4E (0.52) | KDM4EL3MBTL1PIK3CD | |
| SCHEMBL26131264 | 0.77 | DRD2 (0.41) | DRD2KDM4EL3MBTL1 | |
| SCHEMBL22340533 | 0.76 | KDM4E (0.43) | DRD2KDM4EL3MBTL1PIK3CD | |
| SCHEMBL14835760 | 0.75 | L3MBTL1 (0.44) | KDM4EL3MBTL1PIK3CD | |
| SCHEMBL26128730 | 0.75 | L3MBTL1 (0.41) | DRD2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| CN-103429585-B | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2015-07-08 | — | — | CN | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012125598-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | DRD2 822/4885PARP1 93/4885SLC6A2 3049/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | DRD2 314/4885PARP1 432/4885SLC6A2 1573/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | DRD2 4801/4885PARP1 2979/4885SLC6A2 4721/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | DRD2 526/4885PARP1 591/4885SLC6A2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.